SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 4,533 shares, a growth of 1,237.2% from the April 30th total of 339 shares. Based on an average daily volume of 32,028 shares, the days-to-cover ratio is currently 0.1 days.
SAB Biotherapeutics Stock Up 1.2%
Shares of SABSW traded up $0.00 during mid-day trading on Friday, hitting $0.02. 2,000 shares of the company’s stock were exchanged, compared to its average volume of 21,859. SAB Biotherapeutics has a 52 week low of $0.02 and a 52 week high of $0.18. The stock’s 50-day simple moving average is $0.02 and its 200-day simple moving average is $0.03.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Featured Articles
- Five stocks we like better than SAB Biotherapeutics
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
